Akira Yuno

2.0k total citations
29 papers, 844 citations indexed

About

Akira Yuno is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Akira Yuno has authored 29 papers receiving a total of 844 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Immunology and 13 papers in Molecular Biology. Recurrent topics in Akira Yuno's work include Immunotherapy and Immune Responses (13 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Immune Cell Function and Interaction (6 papers). Akira Yuno is often cited by papers focused on Immunotherapy and Immune Responses (13 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Immune Cell Function and Interaction (6 papers). Akira Yuno collaborates with scholars based in United States, Japan and Bangladesh. Akira Yuno's co-authors include Jane B. Trepel, Yusuke Tomita, Yasuharu Nishimura, Masanori Shinohara, Yoshihiro Yoshitake, Sunmin Lee, Masatoshi Hirayama, Min-Jung Lee, Satoru Senju and Hideki Nakayama and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Akira Yuno

29 papers receiving 838 citations

Peers

Countries citing papers authored by Akira Yuno

Since Specialization

Citations

This map shows the geographic impact of Akira Yuno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akira Yuno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akira Yuno more than expected).

Fields of papers citing papers by Akira Yuno

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akira Yuno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akira Yuno. The network helps show where Akira Yuno may publish in the future.

Co-authorship network of co-authors of Akira Yuno

This figure shows the co-authorship network connecting the top 25 collaborators of Akira Yuno. A scholar is included among the top collaborators of Akira Yuno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akira Yuno. Akira Yuno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia 2021 ·Leukemia Research ·Hetty E. Carraway, Yazeed Sawalha, Ivana Gojo, Min-Jung Lee, Sunmin Lee, Yusuke Tomita, Akira Yuno, (unknown), B. Douglas Smith, Keith W. Pratz, Mark J. Levis, Steven D. Gore, Nilanjan Ghosh, Amy E. DeZern, Amanda L. Blackford, Maria R. Baer, Lia Gore, Richard Piekarz, Jane B. Trepel, Judith E. Karp	10
2	In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit 2021 ·Translational Lung Cancer Research ·Yusuke Tomita, Bryan Oronsky, (unknown), Pedro Cabrales, Tony R. Reid, Min-Jung Lee, Akira Yuno, Jonathan Baker, Sunmin Lee, Jane B. Trepel	16
3	Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies 2021 ·Translational Lung Cancer Research ·Mary Zhang, Julie A. Hong, Tricia Kunst, (unknown), (unknown), (unknown), (unknown), Min-Jung Lee, Akira Yuno, Sunmin Lee, Markku Miettinen, R. Taylor Ripley, Chuong D. Hoang, Sacha Gnjatic, Jane B. Trepel, David S. Schrump	9
4	Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer 2021 ·BMC Cancer ·Norikazu Masuda, Kenji Tamura, Hiroyuki Yasojima, Akihiko Shimomura, Masataka Sawaki, Min-Jung Lee, Akira Yuno, Jane B. Trepel, (unknown), Yozo Nishimura, Shigehira Saji, Hiroji Iwata	15
5	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy 2020 ·Clinical Cancer Research ·Matthew D. Hellmann, Pasi A. Jänne, Mateusz Opyrchal, Navid Hafez, Luis E. Raez, Dmitry I. Gabrilovich, Fang Wang, Jane B. Trepel, Min-Jung Lee, Akira Yuno, Sunmin Lee, (unknown), Serap Sankoh, Lei Wang, David Tamang, Emmett V. Schmidt, Michael L. Meyers, Suresh S. Ramalingam, Elaine Shum, Peter Ordentlich	83
6	Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel. 2020 ·Journal of Clinical Oncology ·(unknown), (unknown), Yunkai Yu, Akira Yuno, Min-Jung Lee, Cody J. Peer, Seth M. Steinberg, Liang Cao, Jane B. Trepel, William D. Figg, Raffit Hassan, Ira Pastan, Christine Alewine	2
7	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma 2019 ·Clinical Cancer Research ·Christine Alewine, (unknown), Cody J. Peer, Zishuo I. Hu, Min-Jung Lee, Akira Yuno, (unknown), Anish Thomas, Seth M. Steinberg, Jane B. Trepel, William D. Figg, Raffit Hassan, Ira Pastan	40
8	Abstract 5000: Cell cycle checkpoint kinase (CHK)1 inhibition induces immune modulation in recurrentBRCAwild-type high-grade serous ovarian cancer (HGSOC) patients 2019 ·Erika J. Lampert, Min-Jung Lee, Jane B. Trepel, Akira Yuno, Ashley Cimino‐Mathews, (unknown), Eytan Ruppin, Jayakumar R. Nair, Irene Ekwede, Jungmin Lee	1
9	Soluble IL6R Expressed by Myeloid Cells Reduces Tumor-Specific Th1 Differentiation and Drives Tumor Progression 2017 ·Cancer Research ·Hirotake Tsukamoto, Koji Fujieda, Masatoshi Hirayama, Tokunori Ikeda, Akira Yuno, Keiko Matsumura, Daiki Fukuma, Kimi Araki, Hiroshi Mizuta, Hideki Nakayama, Satoru Senju, Yasuharu Nishimura	46
10	Clinical Evaluation and Biomarker Profiling of Hsp90 Inhibitors 2017 ·Methods in molecular biology ·Akira Yuno, Min-Jung Lee, Sunmin Lee, Yusuke Tomita, (unknown), (unknown), Jane B. Trepel	97
11	Generation of Large Numbers of Antigen-Expressing Human Dendritic Cells Using CD14-ML Technology 2016 ·PLoS ONE ·(unknown), Miwa Haruta, Yusuke Tomita, Keiko Matsumura, Tokunori Ikeda, Akira Yuno, Masatoshi Hirayama, Hideki Nakayama, Hiroshi Mizuta, Yasuharu Nishimura, Satoru Senju	5
12	An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs 2016 ·OncoImmunology ·Masatoshi Hirayama, Yusuke Tomita, Akira Yuno, Hirotake Tsukamoto, Satoru Senju, (unknown), (unknown), Atsushi Irie, Yoshihiro Yoshitake, Daiki Fukuma, Masanori Shinohara, Akinobu Hamada, Hirofumi Jono, Eiji Yuba, Kenji Kono, Koji Yoshida, Takuya Tsunoda, Hideki Nakayama, Yasuharu Nishimura	14
13	Identification of glypican-3-derived long peptides activating both CD8⁺and CD4⁺T cells; prolonged overall survival in cancer patients with Th cell response 2015 ·OncoImmunology ·(unknown), Yusuke Tomita, Akira Yuno, Masatoshi Hirayama, Atsushi Irie, Hirotake Tsukamoto, Satoru Senju, Eiji Yuba, Toshiaki Yoshikawa, Kenji Kono, Tetsuya Nakatsura, Yasuharu Nishimura	30
14	Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS 2014 ·Clinical Cancer Research ·Yoshihiro Yoshitake, Daiki Fukuma, Akira Yuno, Masatoshi Hirayama, Hideki Nakayama, Takuya Tanaka, Masashi Nagata, (unknown), Kenta Kawahara, Yoshihiro Nakagawa, Ryoji Yoshida, Akiyuki Hirosue, Hidenao Ogi, Akimitsu Hiraki, Hirofumi Jono, Akinobu Hamada, Koji Yoshida, Yasuharu Nishimura, Yusuke Nakamura, Masanori Shinohara	123
15	Identification of immunogenic LY6K long peptide encompassing both CD4⁺and CD8⁺T-cell epitopes and eliciting CD4⁺T-cell immunity in patients with malignant disease 2014 ·OncoImmunology ·Yusuke Tomita, Akira Yuno, Hirotake Tsukamoto, Satoru Senju, Yasuhiro Kuroda, Masatoshi Hirayama, (unknown), Junji Yatsuda, (unknown), Atsushi Irie, Akinobu Hamada, Hirofumi Jono, Koji Yoshida, Takuya Tsunoda, Yataro Daigo, Hirotsugu Kohrogi, Yoshihiro Yoshitake, Yusuke Nakamura, Masanori Shinohara, Yasuharu Nishimura	17
16	Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells 2014 ·International Journal of Oncology ·Yoshihiro Nakagawa, Hideki Nakayama, Masashi Nagata, Ryoji Yoshida, Kenta Kawahara, Akiyuki Hirosue, Takuya Tanaka, Akira Yuno, Yuichiro Matsuoka, Taku Kojima, Yoshihiro Yoshitake, Akimitsu Hiraki, Masanori Shinohara	47
17	Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients with induced immune responses and a prolonged OS. 2014 ·Journal of Clinical Oncology ·Yoshihiro Yoshitake, Daiki Fukuma, Akira Yuno, Masatoshi Hirayama, Hideki Nakayama, Takuya Tanaka, Masashi Nagata, Kenta Kawahara, Yoshihiro Nakagawa, Ryoji Yoshida, Hidenao Ogi, Akimitsu Hiraki, Hirofumi Jono, Akinobu Hamada, Koji Yoshida, Takuya Tsunoda, Yasuharu Nishimura, Yusuke Nakamura, Masanori Shinohara	1
18	Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4+ and CD8+ T-cell Epitopes: KIF20A-Specific CD4+ T-cell Immunity in Patients with Malignant Tumor 2013 ·Clinical Cancer Research ·Yusuke Tomita, Akira Yuno, Hirotake Tsukamoto, Satoru Senju, Yasuhiro Kuroda, Masatoshi Hirayama, Atsushi Irie, Kenta Kawahara, Junji Yatsuda, Akinobu Hamada, Hirofumi Jono, Koji Yoshida, Takuya Tsunoda, Hirotsugu Kohrogi, Yoshihiro Yoshitake, Yusuke Nakamura, Masanori Shinohara, Yasuharu Nishimura	50
19	Establishment of HLA-DR4 Transgenic Mice for the Identification of CD4+ T Cell Epitopes of Tumor-Associated Antigens 2013 ·PLoS ONE ·Junji Yatsuda, Atsushi Irie, Kumiko Harada, (unknown), Hirotake Tsukamoto, Satoru Senju, Yusuke Tomita, Akira Yuno, Masatoshi Hirayama, (unknown), Naoki Takeda, Isao Shibuya, Shinji Sogo, Fumihiro Fujiki, Haruo Sugiyama, Masatoshi Eto, Yasuharu Nishimura	6
20	TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells 2012 ·Gene Therapy ·Miwa Haruta, Yusuke Tomita, Akira Yuno, Kimio Matsumura, Tokunori Ikeda, Koutaro Takamatsu, (unknown), (unknown), Y. Nishimura, Satoru Senju	53

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact